Difference between revisions of "Dosulepine-agomelatine"

From Psychiatrienet
Jump to: navigation, search
Line 9: Line 9:
 
| start =  
 
| start =  
 
* '''Day 1:''' simultaneously start administration of agomelatine in a dosage of 25 mg/day.
 
* '''Day 1:''' simultaneously start administration of agomelatine in a dosage of 25 mg/day.
* '''Day 15:''' only continue administration of agomelatine. If necessary, increase dosage of agomelatine to 50 mg/day. }}
+
* '''Day 15:''' continue administration of agomelatine. If necessary, increase dosage of agomelatine to 50 mg/day. }}

Revision as of 12:56, 24 July 2009

dosulepin
Type antidepressant
Group TCA
links
ATC-code N06AA16
PubChem 13473
PubMed dosulepin
Kompas (Dutch) dosulepin
Wikipedia dosulepin
Agomelatine
Type Antidepressant
Group other
links
ATC-code N06AX22
EMEA valdoxan
PubChem 82148
PubMed Agomelatine
Kompas (Dutch) Agomelatine
Wikipedia Agomelatine

Switch medication from dosulepine to agomelatine.

Nietinrijdenbord.png Stop dosulepine
  • Before day 0: gradually reduce dosage of dosulepine to a maximum of 75 mg/day, when this dosage is > 75 mg/day.
  • Day 1: reduce dosage of dosulepine to 50 mg/day.
  • Day 8: reduce dosage of dosulepine to 25 mg/day.
  • Day 15: stop administration of dosulepine.
Eenrichtingbord.png Start agomelatine
  • Day 1: simultaneously start administration of agomelatine in a dosage of 25 mg/day.
  • Day 15: continue administration of agomelatine. If necessary, increase dosage of agomelatine to 50 mg/day.


  1. 1.0 1.1 1.2 1.3 1.4 KNMP; Informatorium Medicamentorum 2015; Monografie "dosulepine" (Dutch)
  2. NVZA; Toxicology.org; Monografie 63 (dutch)
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.